Sonoma Pharmaceuticals, Inc.

SNOA

US83558L2043

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
0.15 ^USD	-4.21%		-14.53%	-16.85%

Feb. 08	Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
Jan. 23	Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-The-Counter Skincare Product for Daily Use	CI

Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022

August 11, 2022 at 04:16 pm EDT

Sonoma Pharmaceuticals, Inc. reported earnings results for the first quarter ended June 30, 2022. For the first quarter, the company reported sales was USD 3.98 million compared to USD 3.68 million a year ago. Net loss was USD 0.887 million compared to USD 1.1 million a year ago. Basic loss per share from continuing operations was USD 0.29 compared to USD 0.52 a year ago. Diluted loss per share from continuing operations was USD 0.29 compared to USD 0.52 a year ago.

Latest news about Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-The-Counter Skincare Product for Daily Use	Jan. 23	CI
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma?s Extensive Distributor Network	Jan. 09	CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 13	CI
Sonoma Pharmaceuticals, Inc. Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation At the Symposium on Advanced Wound Care Fall Conference	Nov. 03	CI
Sector Update: Health Care Stocks Ease in Late Afternoon	23-10-26	MT
Sector Update: Health Care	23-10-26	MT
Top MIdday Decliners	23-10-26	MT
Wall Street Set to Open Lower as GDP, Jobless Claims Higher Than Expected	23-10-26	MT
Ladenburg Thalmann Initiates Coverage on Sonoma Pharmaceuticals at Buy, $3.25 Price Target	23-09-05	MT
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals, Inc. for Reliefacyn Advanced	23-08-15	CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Sonoma Pharmaceuticals, Inc. Announces Appointment of Hye Jin Chung to Scientific Advisory Board	23-08-03	CI
Sonoma Pharmaceuticals, Inc. Appoints John Dal Poggetto as Controller	23-07-14	CI
Earnings Flash (SNOA) SONOMA PHARMACEUTICALS Reports Q4 Revenue $3M	23-06-22	MT
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-21	CI
Sonoma Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-06-20	CI
Top Premarket Gainers	23-06-09	MT
Sonoma Pharmaceuticals, Inc. Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union	23-06-08	CI
Sonoma Pharmaceuticals, Inc. Announces CFO Changes	23-04-13	CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Sonoma Pharmaceuticals Signs Distribution Deal With Daewoong Pharmaceutical to Sell Skin Products in South Korea	23-01-31	MT
Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea	23-01-31	CI
Sector Update: Health Care Stocks Largely Sit Out Late Market Rebound	23-01-25	MT
Sector Update: Health Care Stocks Still Lacking Traction	23-01-25	MT

Chart Sonoma Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Sonoma Pharmaceuticals, Inc. is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The Company's product offerings include Regenacyn Advanced Scar Gel, Regenacyn Plus Scar Gel, Rejuvacyn Advanced Skin Repair Cooling Mist, Pediacyn Skin Care, Microcyn, Ocucyn Eyelid and Eyelash Cleanser, Microdacyn60 Oral Care, Podiacyn Advanced Everyday Foot Care, and MicrocynAH. Regenacyn Advanced Scar Gel helps to improve the overall appearance of scars while reducing pain, itch, redness, and inflammation. Regenacyn Plus is a prescription-strength scar gel which is available as an office dispense product through dermatology practices and medical spas. Pediacyn is a pediatric dermatology and wound care product for over-the-counter use. MicrocynAH is a HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections.

Sector

Pharmaceuticals

Calendar

2024-07-09 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.15 USD

Average target price

3.25 USD

Spread / Average Target

+2,066.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SONOMA PHARMACEUTICALS, INC.	-16.85%	2.44M
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B

Other Pharmaceuticals